Study S001471

A Multicenter, Randomized, Double-blind, Placebo-controlled，Dulaglutide-controlled Phase Ⅱ Trial Exploring Optimal Dosing Regimen for TG103 Injection Monotherapy in Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05348122
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: UNKNOWN
Enrollment: 240
Start: 2022-06-15
Primary completion: 2023-11-01
Lead sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:TG103,Q2W; DRUG:TG103,QW; DRUG:Placebo,Q2W; DRUG:Placebo,QW; DRUG:Dulaglutide,QW
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17 [Baseline through Day 113]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.